Branched-Chain Amino Acids is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is General Hospital of Shenyang Military Region (1). The most-studied condition is Overt Hepatic Encephalopathy.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance
NCT07257562 · ClinicalTrials.gov ↗ · Chronic Hepatitis B
|
Observational | Recruiting | First Affiliated Hospital of Fujian Medical University | China |
|
Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)
NCT06483737 · ClinicalTrials.gov ↗ · Overt Hepatic Encephalopathy
|
Not applicable | Recruiting | General Hospital of Shenyang Military Region | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| General Hospital of Shenyang Military Region | 1 |
| First Affiliated Hospital of Fujian Medical University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Branched-Chain Amino Acids as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
General Hospital of Shenyang Military Region (1) and First Affiliated Hospital of Fujian Medical University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Branched-Chain Amino Acids works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Branched-Chain Amino Acids works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Branched-Chain Amino Acids (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.